Rosen Robert 4
4 · Odonate Therapeutics, Inc. · Filed Dec 12, 2019
Insider Transaction Report
Form 4
Rosen Robert
Director
Transactions
- Award
Stock Option (Right to Buy)
2019-12-10+12,500→ 12,500 totalExercise: $30.51Exp: 2029-12-10→ Common Stock (12,500 underlying)
Footnotes (1)
- [F1]The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date.